FDA flags concerns over unapproved tirzepatide sold for weight loss
The agency's warnings target products outside the approved supply chain, a recurring issue since the shortage-era compounding boom.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 2 02:52 ETSource: polskieradio.pl
The wire
- 01Report describes FDA concerns about unapproved GLP-1 products, including tirzepatide, being used for weight loss.
- 02Pharmacies and telehealth prescribers face continued enforcement risk around non-FDA-approved incretin sourcing.
- 03Specific enforcement actions, product names and sellers were not detailed in the report.
From the source
Read at polskieradio.plfda concerns unapproved glp-1 drugs used for weight loss tirzepatide
